EVALUATION OF THE PERFORMANCE OF MASEF SCORE IN PATIENTS WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) UNDER A LIPID-LOWERING MEDICATION

被引：0
|
作者：
Martinez-Arranz, Ibon [1 ]
Banales, Jesus [2 ]
Alonso, Cristina [1 ]
Mayo, Rebeca [1 ]
Arrese, Marco [3 ]
Crespo, Javier [4 ]
Noureddin, Mazen [5 ]
机构：
[1] OWL Metabol, Derio, Spain
[2] Univ Basque Country, Donostia Univ Hosp, Biodonostia Res Inst, Leioa, Spain
[3] Pontificia Univ Catolica Chile, Santiago, Chile
[4] Marques Valdecilla Univ Hosp, Univ Cantabria, IDIVAL, Santander, Spain
[5] Houston Methodist Hosp, Houston, TX USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
821
引用
收藏
页码：S619 / S620
页数：2
相关论文
共 50 条
  • [31] Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study
    Liao, Xianhua
    Ma, Qianqian
    Wu, Tingfeng
    Shao, Congxiang
    Lin, Yansong
    Sun, Yanhong
    Feng, Shiting
    Wang, Wei
    Ye, Junzhao
    Zhong, Bihui
    DIABETES METABOLIC SYNDROME AND OBESITY, 2022, 15 : 1173 - 1184
  • [32] MORTALITY, HEPATIC DECOMPENSATION, CARDIOVASCULAR AND RENAL RELATED OUTCOMES IN LEAN VERSUS NON-LEAN PATIENTS ADMITTED WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
    Ezeani, Chukwunonso
    Omaliko, Chidiebele E.
    Njei, Basile
    GASTROENTEROLOGY, 2024, 166 (05) : S1628 - S1628
  • [33] Health care resource utilization for patients diagnosed and at high risk of metabolic dysfunction-associated steatohepatitis in Stockholm, Sweden-a REVEAL-MASH study
    Grip, Emilie Toresson
    Apecechea, Nikolas Scheffer
    Basuroy, Ron
    Johansen, Pierre
    Mangla, Kamal Kant
    Skroder, Helena
    Hagstrom, Hannes
    JOURNAL OF HEPATOLOGY, 2024, 80 : S464 - S465
  • [34] USING A DATABASE ANALYSIS TO DETERMINE ALIGNMENT BETWEEN PHYSICIAN-REPORTED AND OBJECTIVELY DERIVED FIBROSIS SCORES FOR US PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
    Gbadamosi, S. O.
    Soule, B. P.
    Higgins, V
    Leith, A.
    Milligan, G.
    VALUE IN HEALTH, 2024, 27 (06) : S356 - S356
  • [35] Mortality, Hepatic Decompensation, and Cardiovascular- and Renal-Related Outcomes in Lean Versus Non-lean Patients Hospitalized With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
    Ezeani, Chukwunonso
    Omaliko, Chidiebele
    Al-Ajlouni, Yazan A.
    Njei, Basile
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [36] Insulin resistance as an independent predictor of metabolic dysfunction-associated steatohepatitis (MASH) severity: combined data from multiple therapeutic trials including more than 10, 000 patients
    Ratziu, Vlad
    Schattenberg, Jorn M.
    Alkhouri, Naim
    Noureddin, Mazen
    Charlton, Michael
    Dubourg, Julie
    Harrison, Stephen A.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S464 - S464
  • [37] Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: A real-world observational analysis of a health claims database
    Kawasaki, Ryo
    Konta, Tsuneo
    Nishida, Kohji
    DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2351 - 2360
  • [38] Evaluation of the safety and potential lipid-lowering effects of oral hydrogen-rich coral calcium (HRCC) capsules in patients with metabolic syndrome: a prospective case series study
    Chiu, Szu-Han
    Douglas, Frank L.
    Chung, Jia-Ru
    Wang, Kuang-Yih
    Chu, Chao-Fang
    Chou, Hsia-Yun
    Huang, Wei-Chih
    Wang, Tian-Yu
    Chen, Wen-Wen
    Shen, Min-Chung
    Liu, Feng-Cheng
    Hsiao, Po-Jen
    FRONTIERS IN NUTRITION, 2023, 10
  • [39] BOS-580, a long-acting FGF-21 analogue, treatment shows beneficial changes in the circulating lipidome and improves MASEF score in patients with phenotypic metabolic dysfunction-associated steatohepatitis in a phase 2a randomized, placebocontrolled, 12-week study
    Bain, Gerard
    Clawson, Alicia
    Lopez-Talavera, Juan Carlos
    Odrljin, Tatjana
    JOURNAL OF HEPATOLOGY, 2024, 80 : S517 - S517
  • [40] BIOMARKER RESPONSE IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) PATIENTS WITH HIGH-RISK BASELINE FAST SCORES: OBSERVATIONS FROM THE ENLIVEN PHASE2B TRIAL WITH PEGOZAFERMIN
    Hartsfield, Cynthia
    Alkhouri, Naim
    Anstee, Quentin
    Loomba, Rohit
    Abdelmalek, Manal
    Kowdley, Kris
    Margalit, Maya
    Gottwald, Mildred
    Agollah, Germaine
    Feng, Shibao
    Mansbach, Hank
    Sanyal, Arun
    HEPATOLOGY, 2024, 80 : S444 - S445
12345